A new study suggests that Medicare could save up to $366 million annually by introducing a new vial size for Alzheimer's drug lecanemab, which is currently only available in single-use, 500- and 200-milligram vials.

Medicare could save up to 74% of the money lost from discarded Alzheimer's drug lecanemab by the simple introduction of a new vial size that would reduce the amount of unused medication that is thrown away.